Abstract

Although most patients with thyroid cancers have good prognosis and long-term survival, some patients are refractory to traditional therapeutic approaches and face a high risk of mortality. CAR-T therapy provides an attractive strategy to treat these patients. Considering the limited expression in thyroid tissues, thyroid-stimulating hormone receptor (TSHR) has been considered as a promising candidate as CAR-T target. However, it is still a challenge to find the optimal CAR design for the treatment of thyroid cancers. Dynamic signaling cascade is initiated by CAR molecules during CAR-T cell activation. The development of FRET-based biosensors enables us to detect the signaling dynamics of key kinases during CAR-T cell activation with high spatiotemporal resolution. Here using the ZAP70 and ERK biosensors, we visualized the dynamics of ZAP70 and ERK activities in TSHR-specific CAR-T cells upon antigen stimulation. We first constructed several TSHR-targeting CARs for the treatment of advanced thyroid cancers. The TSHR CAR-T cells with CD28 or 4-1BB co-stimulatory signaling domains exhibited potent cytotoxicity in vitro. By FRET imaging, we observed rapid increase of ZAP70 and ERK activities in TSHR CAR-T cells upon target cell binding. Even though CD28-based CAR-T cells had similar ZAP70 activation dynamics as 4-1BB-based CAR-T cells, they displayed slightly enhanced ERK activation, which may contribute to their faster anti-tumor kinetics in vivo. These results demonstrated the efficacy of TSHR CAR-T cells to treat advanced thyroid cancers. Our study indicated the potential of applying FRET biosensors to optimize the design of CAR for effective CAR-T therapy.

Highlights

  • Thyroid cancer is the most common endocrine cancer and accounts for 3% of the new cancer cases worldwide in 2020 (Sung et al, 2021)

  • Based on a second-generation cells showed similar expression of biosensor (CAR) construct we investigated the feasibility of Chimeric antigen receptor T (CAR-T) cells in treating thyroid-stimulating hormone receptor (TSHR)-positive thyroid cancers

  • We developed a CAR-T therapy for TSHR-positive advanced thyroid cancers

Read more

Summary

Introduction

Thyroid cancer is the most common endocrine cancer and accounts for 3% of the new cancer cases worldwide in 2020 (Sung et al, 2021). It is reported that the incidence of permanent hypocalcemia and permanent vocal cord paralysis after re-dissection of cervical lymph nodes can be as high as 4.9 and 17.8% respectively, which may seriously affect the quality of patients’ life. For such patients, exploring a new non-invasive treatment method is of great value. It is reported that patients with refractory DTCs have less than 50% of 5-years survival rate (Laha et al, 2020) For these patients, it is urgent to explore new treatment methods

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call